Personalis, Inc. (PSNL): Immune Profiling Powers Growth

Recurring income from pharma services enhances financial resilience, reducing dependence on unpredictable trial outcomes.

Personalis, Inc. (PSNL) is a leader in next-generation immune health, offering advanced assays and analytics to assess how patients’ immune systems interact with cancer. Their flagship product, NeXT Personal, provides deep sequencing of the immune repertoire and personalized epitope mapping to guide immuno-oncology therapies. Growing adoption of immune …